Assessment of Tramadol as a Treatment for Opioid Addiction
Primary Purpose
Opioid-Related Disorders
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Tramadol
Sponsored by
About this trial
This is an interventional treatment trial for Opioid-Related Disorders
Eligibility Criteria
Inclusion Criteria: Currently opioid dependent Exclusion Criteria: Significant medical illness (e.g., diabetes mellitus) History of seizure Current sedative or alcohol dependence Pregnant or breastfeeding
Sites / Locations
- Behavioral Pharmacology Research Unit
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
1
2
Arm Description
tramadol dose 1
tramadol dose 2
Outcomes
Primary Outcome Measures
Self-reported effects
physiologic measures
observer ratings of effects
cognitive/performance measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00301210
First Posted
March 9, 2006
Last Updated
April 16, 2015
Sponsor
Johns Hopkins University
Collaborators
National Institute on Drug Abuse (NIDA)
1. Study Identification
Unique Protocol Identification Number
NCT00301210
Brief Title
Assessment of Tramadol as a Treatment for Opioid Addiction
Official Title
Assessment of the Level of Physical Dependence and Blockade Efficacy Produced by Tramadol
Study Type
Interventional
2. Study Status
Record Verification Date
April 2015
Overall Recruitment Status
Completed
Study Start Date
January 2006 (undefined)
Primary Completion Date
October 2007 (Actual)
Study Completion Date
November 2007 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Johns Hopkins University
Collaborators
National Institute on Drug Abuse (NIDA)
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Opioids are one of the most commonly abused drugs among individuals who seek treatment for drug abuse. Thus, it is necessary to develop new treatments for opioid addiction. The purpose of this trial is determine whether tramadol is effective in treating opioid dependent individuals.
Detailed Description
This human laboratory study will test the effects of tramadol as a step in its development as a new treatment for opioid dependence. Tramadol is a moderate mu agonist opioid that may produce low levels of opioid physical dependence. Tramadol's capacity for producing physical dependence has not been systematically studied in humans. It is important to quantify tramadol, as it provides a measure of its opioid agonist effects. This would also be informative in regards to the abuse liability of tramadol when used as an analgesic (as currently marketed), or when used in the treatment of opioid addiction (as proposed in this study). The purpose of this trial is to evaluate the level of physical dependence as well as blockade efficacy produced by chronic maintenance on oral tramadol in opioid dependent individuals.
Participants will be randomly assigned to receive different doses of tramadol or placebo for up to six weeks. Experimental sessions will take place up to three times per week during the treatment period. During challenge sessions, participants will receive an injection; four different kinds of effects may occur in a session following this injection. First, no effect may occur (a placebo). Second, an opioid agonist effect may occur (opioid agonists include heroin, morphine, hydromorphone, tramadol, and methadone), which may cause the participant to feel "high." Third, an opioid antagonist effect may occur (e.g., naloxone, naltrexone), which may cause the participant to feel a sense of opioid withdrawal.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Opioid-Related Disorders
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
9 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
tramadol dose 1
Arm Title
2
Arm Type
Experimental
Arm Description
tramadol dose 2
Intervention Type
Drug
Intervention Name(s)
Tramadol
Other Intervention Name(s)
Ultram
Intervention Description
oral doses four times per day
Primary Outcome Measure Information:
Title
Self-reported effects
Time Frame
up to 4 hours for acute effects
Title
physiologic measures
Time Frame
up to 4 hours for acute effects
Title
observer ratings of effects
Time Frame
up to 4 hours for acute effects
Title
cognitive/performance measures
Time Frame
up to 4 hours for acute effects
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Currently opioid dependent
Exclusion Criteria:
Significant medical illness (e.g., diabetes mellitus)
History of seizure
Current sedative or alcohol dependence
Pregnant or breastfeeding
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eric C. Strain, MD
Organizational Affiliation
Johns Hopkins University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Behavioral Pharmacology Research Unit
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21224
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
20589494
Citation
Lanier RK, Lofwall MR, Mintzer MZ, Bigelow GE, Strain EC. Physical dependence potential of daily tramadol dosing in humans. Psychopharmacology (Berl). 2010 Sep;211(4):457-66. doi: 10.1007/s00213-010-1919-3. Epub 2010 Jun 30.
Results Reference
result
Learn more about this trial
Assessment of Tramadol as a Treatment for Opioid Addiction
We'll reach out to this number within 24 hrs